Are you above the legal age to view this content in your province/state?

Home / Cannabis Stock Market / Hexo eyes California cannabis market for upcoming investment

Hexo eyes California cannabis market for upcoming investment

Hexo eyes California cannabis market for upcoming investment

Hexo Corp. plans to enter the U.S. cannabis market through an investment in a California-based company that leverages the Canadian company’s manufacturing prowess, the company’s chief executive said Friday.

The company created a special purpose vehicle to invest in the U.S. market while remaining onside with regulatory requirements from the Toronto Stock Exchange and New York Stock Exchange that forbid Canadian cannabis companies from operating in the U.S., which still deems marijuana to be federally illegal, Hexo CEO Sebastien St-Louis said in an interview. 

“The structure we’re looking at is an option structure by which post- [U.S] legalisation, Hexo would own 80 per cent of all the California assets,” St-Louis said. “It’s simply time to get into the market and bring the technology we’ve developed in Canada to the rest of the world and what better place to start than California.”

St-Louis’ comments come as Hexo’s TSX-listed shares fell more than 25 per cent on Friday following an announcement that it raised US$140 million through a public stock offering. The funds are earmarked to help pay for its acquisition of Canadian cannabis operator Redecan Pharm and its U.S. venture. 

While St-Louis didn’t identify which company Hexo was looking to invest in, he said he will bring the same technology the company uses to manufacture its pre-roll and hash cannabis products to California, rather than investing directly in a U.S. multi-state operator. 

“When Hexo becomes their partner and their supplier, we will be able to supply them product below their current cost of goods while still making a very interesting margin for Hexo,” he said.

Hexo’s U.S. strategy appears to differ from what other Canadian cannabis firms are planning to do in the U.S. once politicians fully legalize marijuana. Earlier this week, Tilray Inc. said it was investing in beleaguered cannabis retailer MedMen Enterprises Inc., while Canopy Growth Corp. and Cronos Group Inc. both have struck option deals to acquire large equity stakes in U.S. multi-state operators. 

This article originally appeared on BNN Bloomberg.

Disclaimer

Investment Value Finders specializes in providing opinions and information on stocks to individuals who wish to receive them. Our reports are construed for information purposes solely and are distributed free of charge to individuals who wish to receive them.


Investment Value Finders does not promote, condone or advocate licit or illicit drug use. Investment Value Finders cannot be held responsible for materials or contests posted on its website pages, or pages to which we provide links, which promote, condone or advocate licit or illicit drug use or illegal activities.


DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE. We are not registered as a securities broker-dealer or an investment adviser. We are neither licensed nor qualified to provide investment advice.


Investment Value Finders occasionally receives direct compensation for hosting links (or other* advertisements) to third party content that may be subject to disclaimer pursuant to Section 17(b) of the Securities Act of 1933. For those instances where the link text contains company or stock-specific mention, we provide the following list of compensation received in order to ensure full disclosure and transparency.


Investment Value Finders is intended for those 21+ years of age only!

Check Also

FSD Pharma Announces Closing of Lucid Psycheceuticals Acquisition

FSD Pharma Announces Closing of Lucid Psycheceuticals Acquisition

Lucid Adds Potential for Neurodegenerative Disease Treatments and Mental Health in a Novel Way TORONTO–(BUSINESS …